A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors

• Protocol Number: 202509215
• Principal Investigator: Johanns, Tanner
• Cancer Types: Early Phase

Learn more about this study at: clinicaltrials.gov